Shenzhen Geno-Immune Medical Institute

Country

Ownership: Private

Established: 2015-04-28

Employees: -

Market Cap: -

Website

Clinical Trials

Multi-CAR T Cell Therapy in the Treatment of Multiple Myeloma

Phase 1

Conditions: Multiple Myeloma

Interventions: Biological: CAR T cells

First Posted Date: 2017-09-05

Last Posted Date: 2019-09-19

Lead Sponsor: Shenzhen Geno-Immune Medical Institute

Target Recruit Count: 20

Registration Number: NCT03271632

Locations: 🇨🇳
Shenzhen Geno-immune Medical Institute, Shenzhen, Guangdong, China
🇨🇳
The First People's Hospital of Yunnan, Kunming, Yunnan, China

Multi-CAR T Cell Therapy for Acute Myeloid Leukemia

Phase 1

Conditions: Acute Myeloid Leukemia

Interventions: Biological: Muc1/CLL1/CD33/CD38/CD56/CD123-specific gene-engineered T cells

First Posted Date: 2017-07-19

Last Posted Date: 2018-10-17

Lead Sponsor: Shenzhen Geno-Immune Medical Institute

Target Recruit Count: 10

Registration Number: NCT03222674

Locations: 🇨🇳
Yunnan Cancer Hospital & The Third Affiliated Hospital of Kunming Medical University & Yunnan Cancer Center, KunMing, Yunnan, China
🇨🇳
Zhujiang Hospital of Southern Medical University, Guangzhou, Guangdong, China
🇨🇳
Shenzhen Geno-immune Medical Institute, Shenzhen, Guangdong, China

SCID-X1 Gene Therapy Via Intravenous Lentiviral (Ivlv-X1) Injection

Phase 1

Recruiting

Conditions: SCID, X-Linked

Interventions: Biological: Direct intravenous injection of ivlv-X1 lentiviral vector

First Posted Date: 2017-07-14

Last Posted Date: 2024-07-08

Lead Sponsor: Shenzhen Geno-Immune Medical Institute

Target Recruit Count: 10

Registration Number: NCT03217617

Locations: 🇨🇳
Shenzhen Geno-immune Medical Institute, Shenzhen, Guangdong, China
🇨🇳
Guilin Hospital of Chinese Traditional and Western Medicine, Guilin, Guangxi, China

Lentiviral FVIII Gene Therapy

Phase 1

Conditions: Hemophilia A

Interventions: Biological: YUVA-GT-F801

First Posted Date: 2017-07-13

Last Posted Date: 2019-05-23

Lead Sponsor: Shenzhen Geno-Immune Medical Institute

Target Recruit Count: 10

Registration Number: NCT03217032

Locations: 🇨🇳
Shenzhen Geno-immune Medical Institute, Shenzhen, Guangdong, China

Genetically Modified T Cells Against Ovarian Cancer

Phase 1

Conditions: Ovarian Cancer

Interventions: Biological: OC-IgT cells

First Posted Date: 2017-06-14

Last Posted Date: 2020-03-19

Lead Sponsor: Shenzhen Geno-Immune Medical Institute

Target Recruit Count: 100

Registration Number: NCT03184753

Locations: 🇨🇳
Shenzhen Geno-immune Medical Institute, Shenzhen, Guangdong, China

Intervention of Bladder Cancer by CAR-T

Phase 1

Conditions: Bladder Cancer
Urothelial Carcinoma Bladder

Interventions: Genetic: 4SCAR-PSMA
Genetic: 4SCAR-FRa

First Posted Date: 2017-06-14

Last Posted Date: 2019-09-19

Lead Sponsor: Shenzhen Geno-Immune Medical Institute

Target Recruit Count: 20

Registration Number: NCT03185468

Locations: 🇨🇳
Shenzhen Second People Hospital, Shenzhen, Gongdong, China
🇨🇳
Shenzhen Geno-immune Medical Institute, Shenzhen, Guangdong, China

Immunogene-modified T (IgT) Cells Against Glioblastoma Multiforme

Phase 1

Conditions: Glioblastoma Multiforme
Glioblastoma Multiforme of Brain

Interventions: Biological: Antigen-specific IgT cells

First Posted Date: 2017-05-30

Last Posted Date: 2023-01-17

Lead Sponsor: Shenzhen Geno-Immune Medical Institute

Target Recruit Count: 20

Registration Number: NCT03170141

Locations: 🇨🇳
Shenzhen People's Hospital, Shenzhen, Guangdong, China
🇨🇳
Shenzhen Geno-immune Medical Institute, Shenzhen, Guangdong, China

Antigen-specific Cytotoxic T Cells in the Treatment of Opportunistic Infections

Phase 1

Conditions: BKV Infection
CMV Infection
Adenovirus Infection
Fungus Infection
Tuberculosis
EBV Infection
Pathogen Infection

Interventions: Biological: pathogen-specific CTLs

First Posted Date: 2017-05-18

Last Posted Date: 2019-09-19

Lead Sponsor: Shenzhen Geno-Immune Medical Institute

Target Recruit Count: 100

Registration Number: NCT03159364

Locations: 🇨🇳
Shenzhen Geno-immune Medical Institute, Shenzhen, Guangdong, China

Combination CAR-T Cell Therapy Targeting Hematological Malignancies

Phase 1

Conditions: B-cell Malignancies

Interventions: Biological: 4SCAR19 and 4SCAR22
Biological: 4SCAR19 and 4SCAR38
Biological: 4SCAR19 and 4SCAR20
Biological: 4SCAR19 and 4SCAR123
Biological: 4SCAR19 and 4SCAR70
Biological: 4SCAR19 and 4SCAR30

First Posted Date: 2017-04-24

Last Posted Date: 2019-09-19

Lead Sponsor: Shenzhen Geno-Immune Medical Institute

Target Recruit Count: 100

Registration Number: NCT03125577

Locations: 🇨🇳
Shenzhen Geno-immune Medical Institute, Shenzhen, Guangdong, China
🇨🇳
Yunnan Cancer Hospital & The Third Affiliated Hospital of Kunming Medical University & Yunnan Cancer Center, Kunming, Yunnan, China
🇨🇳
Zhujiang Hospital of Southern Medical University, Guangzhou, Guangdong, China

Clonal Fetal Mesenchymal Stem Cells (cfMSCs) for the Control of Immune-related Disorders

Phase 1

Conditions: Immune Related Disorder
Tissue Damage

Interventions: Biological: clonal fetal MSCs

First Posted Date: 2017-04-21

Last Posted Date: 2018-02-26

Lead Sponsor: Shenzhen Geno-Immune Medical Institute

Target Recruit Count: 100

Registration Number: NCT03123458

Locations: 🇨🇳
Shenzhen Geno-immune Medical Institute, Shenzhen, Guangdong, China
🇨🇳
Capital Institute of Pediatrics affiliated Children's hospital, Beijing, Beijing, China
🇨🇳
Aerospace Center Hospital, Beijing, China

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy